Deutsche Bank Ag\ Galera Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$1.27 - $8.28 $350,437 - $2.28 Million	-275,935 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$6.08 - $10.44 $1.64 Million - $2.82 Million	269,758 Added 4367.14%	275,935 $2.71 Million
Q1 2021 May 13, 2021	SELL	$8.35 - $12.39 $4,483 - $6,653	-537 Reduced 8.0%	6,177 $54,000
Q4 2020 Feb 16, 2021	BUY	$8.02 - $12.81 $18,197 - $29,065	2,269 Added 51.05%	6,714 $69,000
Q3 2020 Nov 12, 2020	BUY	$6.96 - $9.12 $2,923 - $3,830	420 Added 10.43%	4,445 $40,000
Q2 2020 Aug 13, 2020	BUY	$7.14 - $14.41 $24,975 - $50,406	3,498 Added 663.76%	4,025 $29,000
Q1 2020 May 14, 2020	SELL	$5.89 - $17.67 $212 - $636	-36 Reduced 6.39%	527 $5,000
Q4 2019 Feb 14, 2020	BUY	$9.13 - $13.9 $5,140 - $7,825	563 New	563 $7,000

961K

Ticker GRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,821,600
Market Cap $1.34M
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.